In companion cases Acorda Therapeutics Inc. v. Mylan Pharm, Inc. (No. 2015-1456) and AstraZeneca AB v. Mylan Pharm. Inc. (No. 2015-1460), the Federal Circuit held that the District of Delaware may exercise specific jurisdiction over generic pharmaceutical company Mylan because Mylan’s ANDA filings and its distribution capabilities establish that it plans to market generic versions of Acorda’s and AstraZeneca’s drug products in Delaware. The majority opinion declined to reach the question of whether Mylan’s compliance with Delaware’s statute requiring that foreign corporations that register to do business in the state appoint an agent for service of process is a valid form of consent to general personal jurisdiction.